Research programme: macromolecular drug conjugates - Prolynx

Drug Profile

Research programme: macromolecular drug conjugates - Prolynx

Alternative Names: Hydrogel-exenatide - Prolynx; Hydrogel-octreotide - Prolynx; PEG-exenatide - Prolynx; PEG-octreotide - Prolynx; PLX 039

Latest Information Update: 28 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Prolynx
  • Class Camptothecins; Drug conjugates; Polyethylene glycols
  • Mechanism of Action DNA topoisomerase I inhibitors; Glucagon like peptide 1 receptor agonists; Growth hormone releasing factor antagonists; Somatostatin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Acromegaly; Cancer; Type 2 diabetes mellitus

Highest Development Phases

  • Preclinical Cancer; Ear disorders; Obesity; Type 2 diabetes mellitus
  • No development reported Acromegaly

Most Recent Events

  • 24 Jun 2017 Preclinical trials in Type-2 diabetes mellitus and Obesity in USA (SC) (Prolynx website, June 2017)
  • 12 Jun 2017 Pharmacodynamics data from preclinical trials in Type 2 diabetes mellitus released by ProLynx
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acromegaly in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top